ID

35801

Descripción

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms; ODM derived from: https://clinicaltrials.gov/show/NCT02298192

Link

https://clinicaltrials.gov/show/NCT02298192

Palabras clave

Versiones (1)
  1. 24/3/19 24/3/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

24 de marzo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes NCT02298192

Inglés

Eligibility Diabetes NCT02298192

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT02298192
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
male or female equal to or above 18 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
hba1c (glycosylated haemoglobin) 7.0 - 10.0% [53 mmol/mol - 86 mmol/mol] (both inclusive), confirmed by the central laboratory
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
stable daily treatment with metformin (above or equal to 1500 mg or max tolerated dose) with or without pioglitazone (above orequal to 30 mg) for at least 90 days prior to screening
Descripción

Metformin Stable U/day | Metformin Maximum Tolerated Dose | Pioglitazone Dosage | Pioglitazone Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0205360
UMLS CUI [1,3]
C0456683
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0752079
UMLS CUI [3,1]
C0071097
UMLS CUI [3,2]
C0178602
UMLS CUI [4,1]
C0071097
UMLS CUI [4,2]
C0332197
body mass index (bmi) below or equal to 40 kg/m^2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
current use of any anti-diabetic drugs (except for metformin and pioglitazone) or anticipated change in concomitant medication, which, in the opinion of the investigator, could interfere with the glucose metabolism (e.g. systemic corticosteroids)
Descripción

Antidiabetics | Exception Metformin | Exception Pioglitazone | Change of medication Interferes with Glucose metabolism | CORTICOSTEROIDS FOR SYSTEMIC USE

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0935929
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0071097
UMLS CUI [4,1]
C0580105
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0596620
UMLS CUI [5]
C3653708
previous and / or current treatment with insulin (short term treatment due to intercurrent illness, including gestational diabetes, is allowed at the discretion of the investigator)
Descripción

Insulin regime | Exception Therapeutic procedure short-term Comorbidity | Exception Therapeutic procedure short-term Gestational Diabetes

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0557978
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0443303
UMLS CUI [2,4]
C0009488
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C0443303
UMLS CUI [3,4]
C0085207
treatment with glucagon-like peptide-1 (glp-1) receptor agonists, sulpfonylurea, glinides, dipeptidyl peptidase 4 (dpp-4) inhibitors or sodium-glucose co-transporter 2 (sglt2) inhibitors within 90 days prior to the screening visit
Descripción

GLP-1 Receptor Agonist | Sulfonylurea | Glinide | Dipeptidyl Peptidase-4 Inhibitor | SGLT2 Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2917359
UMLS CUI [2]
C0038766
UMLS CUI [3]
C2266929
UMLS CUI [4]
C3537225
UMLS CUI [5]
C3273807
impaired liver function, defined as alanine aminotransferase (alat) above or equal to 2.5 times upper normal range (unr)
Descripción

Liver Dysfunction | Alanine aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C0151905
impaired renal function defined as serum-creatinine above or equal to 133 micromol/l (above or equal to 1.5 mg/dl) for males and above or equal to 125 micromol/l (above or equal to 1.4 mg/dl) for females, or as defined according to local contraindications for metformin
Descripción

Renal Insufficiency | Creatinine measurement, serum | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
UMLS CUI [3]
C0079399
screening calcitonin above or equal to 50 ng/l
Descripción

Calcitonin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201924
proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment, according to investigator's clinical judgment
Descripción

Proliferative retinopathy Treatment required for | Disorder of macula of retina Treatment required for | Macular retinal edema Treatment required for

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0339467
UMLS CUI [1,2]
C0332121
UMLS CUI [2,1]
C0730362
UMLS CUI [2,2]
C0332121
UMLS CUI [3,1]
C0271051
UMLS CUI [3,2]
C0332121
personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia type 2 (men2)
Descripción

Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0238462
UMLS CUI [2]
C1833921
UMLS CUI [3,1]
C0027662
UMLS CUI [3,2]
C0332307
history of pancreatitis (acute or chronic)
Descripción

Pancreatitis | Pancreatitis, Chronic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030305
UMLS CUI [2]
C0149521
Volver a la parte superior de la página

Similar models

Eligibility Diabetes NCT02298192

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT02298192
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Age
Item
male or female equal to or above 18 years of age
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c (glycosylated haemoglobin) 7.0 - 10.0% [53 mmol/mol - 86 mmol/mol] (both inclusive), confirmed by the central laboratory
boolean
C0474680 (UMLS CUI [1])
Metformin Stable U/day | Metformin Maximum Tolerated Dose | Pioglitazone Dosage | Pioglitazone Absent
Item
stable daily treatment with metformin (above or equal to 1500 mg or max tolerated dose) with or without pioglitazone (above orequal to 30 mg) for at least 90 days prior to screening
boolean
C0025598 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0025598 (UMLS CUI [2,1])
C0752079 (UMLS CUI [2,2])
C0071097 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0071097 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Body mass index
Item
body mass index (bmi) below or equal to 40 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antidiabetics | Exception Metformin | Exception Pioglitazone | Change of medication Interferes with Glucose metabolism | CORTICOSTEROIDS FOR SYSTEMIC USE
Item
current use of any anti-diabetic drugs (except for metformin and pioglitazone) or anticipated change in concomitant medication, which, in the opinion of the investigator, could interfere with the glucose metabolism (e.g. systemic corticosteroids)
boolean
C0935929 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0071097 (UMLS CUI [3,2])
C0580105 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0596620 (UMLS CUI [4,3])
C3653708 (UMLS CUI [5])
Insulin regime | Exception Therapeutic procedure short-term Comorbidity | Exception Therapeutic procedure short-term Gestational Diabetes
Item
previous and / or current treatment with insulin (short term treatment due to intercurrent illness, including gestational diabetes, is allowed at the discretion of the investigator)
boolean
C0557978 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0443303 (UMLS CUI [2,3])
C0009488 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0443303 (UMLS CUI [3,3])
C0085207 (UMLS CUI [3,4])
GLP-1 Receptor Agonist | Sulfonylurea | Glinide | Dipeptidyl Peptidase-4 Inhibitor | SGLT2 Inhibitor
Item
treatment with glucagon-like peptide-1 (glp-1) receptor agonists, sulpfonylurea, glinides, dipeptidyl peptidase 4 (dpp-4) inhibitors or sodium-glucose co-transporter 2 (sglt2) inhibitors within 90 days prior to the screening visit
boolean
C2917359 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
C2266929 (UMLS CUI [3])
C3537225 (UMLS CUI [4])
C3273807 (UMLS CUI [5])
Liver Dysfunction | Alanine aminotransferase increased
Item
impaired liver function, defined as alanine aminotransferase (alat) above or equal to 2.5 times upper normal range (unr)
boolean
C0086565 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Renal Insufficiency | Creatinine measurement, serum | Gender
Item
impaired renal function defined as serum-creatinine above or equal to 133 micromol/l (above or equal to 1.5 mg/dl) for males and above or equal to 125 micromol/l (above or equal to 1.4 mg/dl) for females, or as defined according to local contraindications for metformin
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Calcitonin measurement
Item
screening calcitonin above or equal to 50 ng/l
boolean
C0201924 (UMLS CUI [1])
Proliferative retinopathy Treatment required for | Disorder of macula of retina Treatment required for | Macular retinal edema Treatment required for
Item
proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment, according to investigator's clinical judgment
boolean
C0339467 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0730362 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C0271051 (UMLS CUI [3,1])
C0332121 (UMLS CUI [3,2])
Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type
Item
personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia type 2 (men2)
boolean
C0238462 (UMLS CUI [1])
C1833921 (UMLS CUI [2])
C0027662 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
Pancreatitis | Pancreatitis, Chronic
Item
history of pancreatitis (acute or chronic)
boolean
C0030305 (UMLS CUI [1])
C0149521 (UMLS CUI [2])
Volver a la parte superior de la página 

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial